GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cassava Sciences Inc (NAS:SAVA) » Definitions » Cyclically Adjusted PB Ratio

Cassava Sciences (Cassava Sciences) Cyclically Adjusted PB Ratio : 5.11 (As of May. 26, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Cassava Sciences Cyclically Adjusted PB Ratio?

As of today (2024-05-26), Cassava Sciences's current share price is $21.715. Cassava Sciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $4.25. Cassava Sciences's Cyclically Adjusted PB Ratio for today is 5.11.

The historical rank and industry rank for Cassava Sciences's Cyclically Adjusted PB Ratio or its related term are showing as below:

SAVA' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.07   Med: 1.13   Max: 9.9
Current: 5.1

During the past years, Cassava Sciences's highest Cyclically Adjusted PB Ratio was 9.90. The lowest was 0.07. And the median was 1.13.

SAVA's Cyclically Adjusted PB Ratio is ranked worse than
79.63% of 653 companies
in the Biotechnology industry
Industry Median: 1.73 vs SAVA: 5.10

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Cassava Sciences's adjusted book value per share data for the three months ended in Mar. 2024 was $1.817. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $4.25 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Cassava Sciences Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Cassava Sciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cassava Sciences Cyclically Adjusted PB Ratio Chart

Cassava Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.93 1.68 10.39 6.92 5.16

Cassava Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.49 5.47 3.67 5.16 4.77

Competitive Comparison of Cassava Sciences's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Cassava Sciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cassava Sciences's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cassava Sciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Cassava Sciences's Cyclically Adjusted PB Ratio falls into.



Cassava Sciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Cassava Sciences's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=21.715/4.25
=5.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cassava Sciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Cassava Sciences's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.817/131.7762*131.7762
=1.817

Current CPI (Mar. 2024) = 131.7762.

Cassava Sciences Quarterly Data

Book Value per Share CPI Adj_Book
201406 6.678 100.560 8.751
201409 6.304 100.428 8.272
201412 6.128 99.070 8.151
201503 5.880 99.621 7.778
201506 5.499 100.684 7.197
201509 5.059 100.392 6.641
201512 4.493 99.792 5.933
201603 3.868 100.470 5.073
201606 3.487 101.688 4.519
201609 3.082 101.861 3.987
201612 2.827 101.863 3.657
201703 2.537 102.862 3.250
201706 2.012 103.349 2.565
201709 1.723 104.136 2.180
201712 1.471 104.011 1.864
201803 1.494 105.290 1.870
201806 1.239 106.317 1.536
201809 1.160 106.507 1.435
201812 1.140 105.998 1.417
201903 1.077 107.251 1.323
201906 1.035 108.070 1.262
201909 1.013 108.329 1.232
201912 1.012 108.420 1.230
202003 1.004 108.902 1.215
202006 0.970 108.767 1.175
202009 0.937 109.815 1.124
202012 2.616 109.897 3.137
202103 7.028 111.754 8.287
202106 6.910 114.631 7.943
202109 6.686 115.734 7.613
202112 6.345 117.630 7.108
202203 5.923 121.301 6.434
202206 5.446 125.017 5.740
202209 4.961 125.227 5.220
202212 5.452 125.222 5.737
202303 4.886 127.348 5.056
202306 4.279 128.729 4.380
202309 3.682 129.860 3.736
202312 3.255 129.419 3.314
202403 1.817 131.776 1.817

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cassava Sciences  (NAS:SAVA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Cassava Sciences Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Cassava Sciences's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cassava Sciences (Cassava Sciences) Business Description

Traded in Other Exchanges
Address
6801 N. Capital of Texas Highway, Suite 300, Building 1, Austin, TX, USA, 78731
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms.
Executives
Sanford Robertson director ONE LETTERMAN DRIVE, BUILDING C SUITE 410, SAN FRANCISCO CA 94129
Richard Barry director 285 MARGALITA DRIVE, SAN RAFAEL CA 94901
Robert Christopher Cook officer: SVP & General Counsel 6801 N. CAPITAL OF TEXAS HWY, BUILDING 1, SUITE 300, AUSTIN TX 78731
James William Kupiec officer: Chief Clinical Dev. Officer 7801 N CAPITAL OF TEXAS HIGHWAY, SUITE 260, AUSTIN TX 78731
Eric Schoen officer: Chief Financial Officer 7801 N. CAPITAL OF TX HWY, SUITE 260, AUSTIN TX 78731
Remi Barbier director, 10 percent owner, officer: CEO, Chairman of the Board
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
O Donnell Michael J director
Robert Z Gussin director
Scannon Patrick J Md Phd director C/O XOMA, LTD., 2910 SEVENTH STREET, BERKELEY CA 94710
Saira Ramasastry director 501 CANAL BLVD., RICHMOND CA 94804
Nadav Friedmann director, officer: Chief Scientific Officer
Sabretooth Master Fund, L.p. 10 percent owner 405 LEXINGTON AVENUE, 50TH FLOOR, NEW YORK NY 10174